These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26036354)

  • 21. Evaluation of metabolism-mediated herb-drug interactions.
    Na DH; Ji HY; Park EJ; Kim MS; Liu KH; Lee HS
    Arch Pharm Res; 2011 Nov; 34(11):1829-42. PubMed ID: 22139684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
    Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
    Clin Pharmacokinet; 2011 Jan; 50(1):25-39. PubMed ID: 21142266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).
    Markowitz JS; DeVane CL
    Psychopharmacol Bull; 2001; 35(1):53-64. PubMed ID: 12397870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
    Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
    JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.
    Fichtenbaum CJ; Gerber JG
    Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.
    Holtzman C; Armon C; Tedaldi E; Chmiel JS; Buchacz K; Wood K; Brooks JT;
    J Gen Intern Med; 2013 Oct; 28(10):1302-10. PubMed ID: 23605401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-herb interactions: eliminating toxicity with hard drug design.
    Yang XX; Hu ZP; Duan W; Zhu YZ; Zhou SF
    Curr Pharm Des; 2006; 12(35):4649-64. PubMed ID: 17168768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort.
    Dasgupta A
    Ther Drug Monit; 2008 Apr; 30(2):212-7. PubMed ID: 18367983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical drugs that interact with St. John's wort and implication in drug development.
    Di YM; Li CG; Xue CC; Zhou SF
    Curr Pharm Des; 2008; 14(17):1723-42. PubMed ID: 18673195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
    Marzolini C; Gibbons S; Khoo S; Back D
    J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risks and synergies from drug interactions.
    Sahai J
    AIDS; 1996 Nov; 10 Suppl 1():S21-5. PubMed ID: 8970672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond!
    Nowack R
    Nephrology (Carlton); 2008 Jun; 13(4):337-47. PubMed ID: 18363644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDR- and CYP3A4-mediated drug-herbal interactions.
    Pal D; Mitra AK
    Life Sci; 2006 Mar; 78(18):2131-45. PubMed ID: 16442130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
    Regazzi M; Carvalho AC; Villani P; Matteelli A
    Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
    Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis.
    Sombogaard F; Franssen EJF; Terpstra WE; Kerver ED; van den Berk GEL; Crul M
    Int J Clin Pharm; 2018 Oct; 40(5):1402-1408. PubMed ID: 29948741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.
    Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Cui Y; Ang CY
    Clin Pharmacol Ther; 2002 Sep; 72(3):276-87. PubMed ID: 12235448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.